Trial updateGlaucoma
A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage
Recruiting. Phase 1 / Phase 2. Registered enrolment: 156. Astellas Pharma Global Development, Inc.
Why it matters
Track this study through NCT07770685. No results are posted in this registry record.
The study at a glance
- Registry status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Registered enrolment
- 156
- Results posted
- No
- Sponsor
- Astellas Pharma Global Development, Inc.
Keep in mind
Registry information describes the study; recruitment status alone does not establish efficacy or safety.